Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Opalesque Search - enter search text below (options..)
Search term:  string and or
Case sensitive Search articles headlines only
Specify publication: 
All publication dates Today Yesterday Last 7 days Last 30 days Last 90 days Last 365 days
Publication dates from: search to: search  NB. All dates are dd/mm/yyyy.

HELPCENTER



Thu, 15 Oct 2009
Founding Father Q&A: Managed futures as part of a broader investment business: How does it work?
Futures Lab: Asset flows in the past 18 months offer an suggestive picture of investor behavior
Insider Talk: A CTA branches out to manage a public fund
Manager Profile: An array of new products from Man Group
Regulators & Courts: Futures vs. securities regulation: Can harmony be achieved?
Top Ten: Australian managed futures and macro funds
 Download as PDF 
Tue, 29 Sep 2009
Founding Father Q&A: Ken Steben of Steben & Co. describes a rigorous CTA screening process
Futures Lab: Comparing returns for long holding periods reveals an interesting difference
Insider Talk: Adam Rochlin of MF Global talks about the brokerage’s new investment platform for CTAs and global macro
Practitioner Viewpoint: Executives from Lyxor, Lighthouse Partners and other firms discussed managed accounts at an event. We bring you the highlights
News Briefs: Trend follower gains, CTA at SEC, high frequency trading, new quantitative index and more
Top Ten: A global macro lineup that includes Bridgewater
 Download as PDF 
Mon, 14 Sep 2009
Founding Father Q&A: Get an inside look at Millburn, a rare example of a futures-based investment management company with a track record that goes back more than three decades
Futures Lab: To build a diversified client base, understand investor characteristics.
Insider Talk: Insight from Abbey Capital regarding global macro strategies and liquidity.
Practitioner Viewpoint: Is there a seasonal pattern in managed futures returns? Here are the evidence and arguments.
News Briefs: Royal Bank of Scotland, Man Group, Barclays Capital, AlphaMetrix, MF Global, and more.
Top Ten: Best performing small CTAs for July.
 Download as PDF 
Tue, 11 Aug 2009
Founding Father Q&A - Investing in global macro and CTAs in the current environment: pros, cons and where the value is. Nick England from Channel Islands Alternatives offers pointers as to what's attractive for investors right now.
Futures Lab: New priorities in asset allocation and due diligence, from Welton Corp.
Insider Talk Understanding quantitative macro: the managers of Numbers discuss their hybrid system.
Index Tracker: Analysis of managed futures and global macro returns.
Manager Profile Lafayette Trading had a nice gain in H1 2009, while CTAs as whole are in the red. How did Lafayette do it?
Practitioner Viewpoint What’s going on with volatility? Quiet can alternate with wild swings, argues Alan Rohrbach.
Top Ten We have a surprise for you: the best global macro funds from a private bank’s database.
 Download as PDF 
Wed, 15 Jul 2009
Founding Father: Jon Sundt of Altegris has picked some of the most successful commodity trading advisors early in their careers and allocated around $4 billion over the years. Here he explains how he makes investment decisions
Futures Lab: There are huge differences among commodity trading advisors. What does this mean for investors?
Insider Talk: Daniel Masters, co-founder of Global Advisors and former head of energy trading at JP Morgan, discusses recent developments in commodity markets
Practitioner Viewpoint: Walker Todd, an attorney and economist who worked for many years in the Federal Reserve System, sees danger in agricultural commodities
News Briefs: Asset Flows, New Exchange, Changes at Brokerage and more
Regulators & Courts: Hearing on position limits: Implications for commodity markets
Top Ten: Highest-Return Programs for10 years
 Download as PDF 

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for